The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival

Am J Surg. 2009 Mar;197(3):403-7. doi: 10.1016/j.amjsurg.2008.11.014.

Abstract

Background: The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers.

Methods: Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002.

Results: There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002).

Conclusions: HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.

MeSH terms

  • Aged
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / physiopathology*
  • Estrogen Replacement Therapy*
  • Female
  • Humans
  • Middle Aged
  • Postmenopause
  • Survival Analysis